Volume 65, Issue 6, Pages (June 2004)

Slides:

Advertisements

Similar presentations

Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.

Advertisements

Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.

Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.

Stephen P. McDonald, Graeme R. Russ Kidney International

Improved prognosis of diabetic nephropathy in type 1 diabetes

Volume 55, Issue 2, Pages (February 1999)

Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD Akshay S. Desai, MD, MPH,

Mitchell H. Rosner, W. Kline Bolton Kidney International

No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease Kevin E. Chan, Ravi I. Thadhani,

Volume 83, Issue 3, Pages (March 2013)

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria Paul E. De Jong, Barry M. Brenner Kidney International

Volume 79, Issue 12, Pages (June 2011)

Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy Misghina Weldegiorgis, Dick de Zeeuw, Liang Li,

Update on Diabetic Nephropathy: Core Curriculum 2018

Volume 67, Issue 6, Pages (June 2005)

Volume 80, Issue 1, Pages (July 2011)

Peter Rossing, Philip Hougaard, Hans-Henrik Parving

Mortality caused by sepsis in patients with end-stage renal disease compared with the general population Mark J. Sarnak, Bertrand L. Jaber Kidney International

Volume 86, Issue 4, Pages (October 2014)

Need for better diabetes treatment for improved renal outcome

Volume 55, Issue 2, Pages (February 1999)

Volume 57, Pages S32-S37 (April 2000)

Volume 79, Issue 12, Pages (June 2011)

Volume 63, Issue 4, Pages (April 2003)

Volume 66, Issue 3, Pages (September 2004)

Steven G. Coca, Swathi Singanamala, Chirag R. Parikh

Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease Johannes F.E. Mann, Qi-Long.

C.Y. Hsu, J.D. Ordoñez, G.M. Chertow, D. Fan, C.E. McCulloch, A.S. Go

Progression of diabetic nephropathy

Comorbidity and confounding in end-stage renal disease

Survival advantage in Asian American end-stage renal disease patients1

Volume 82, Issue 3, Pages (August 2012)

Volume 70, Issue 11, Pages (December 2006)

Volume 67, Issue 4, Pages (April 2005)

Renal risk scores: Progress and prospects

U-shaped effect of eGFR and mortality

Volume 71, Issue 6, Pages (March 2007)

Volume 70, Issue 12, Pages (December 2006)

Volume 67, Pages S48-S51 (January 2005)

Volume 69, Issue 9, Pages (May 2006)

Update on Diabetic Nephropathy: Core Curriculum 2018

Volume 53, Issue 4, Pages (April 1998)

Volume 69, Issue 12, Pages (June 2006)

Proteinuria and hypertensive nephrosclerosis in African Americans

Elevated risk of stroke among patients with end-stage renal disease

Volume 87, Issue 1, Pages (January 2015)

The kidney, a cardiovascular risk marker, and a new target for therapy

Lynda Anne Szczech, Ira L. Lazar Kidney International

Volume 74, Issue 5, Pages (September 2008)

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Improved prognosis of diabetic nephropathy in type 1 diabetes

Volume 60, Issue 1, Pages (July 2001)

Prehypertension: is it relevant for nephrologists?

Volume 62, Issue 3, Pages (September 2002)

Stephen P. McDonald, Graeme R. Russ Kidney International

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: The African American Study of Kidney Disease and Hypertension (AASK) trial

Low triiodothyronine and survival in end-stage renal disease

Volume 70, Issue 7, Pages (October 2006)

Volume 60, Issue 3, Pages (September 2001)

Michael R. Lattanzio, Matthew R. Weir Kidney International

Volume 70, Issue 3, Pages (August 2006)

Volume 62, Pages S68-S72 (December 2002)

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Collecting and using patient and treatment center data to improve care: Adequacy of hemodialysis and end-stage renal disease surveillance1 William M.

Volume 68, Issue 3, Pages (September 2005)

Volume 70, Issue 10, Pages (November 2006)

Volume 57, Issue 2, Pages (October 2000)

Volume 79, Issue 10, Pages (May 2011)

Presentation transcript:

Volume 65, Issue 6, Pages 2309-2320 (June 2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL Dick de Zeeuw, Giuseppe Remuzzi, Hans-Henrik Parving, William F. Keane, Zhongxin Zhang, Shahnaz Shahinfar, Steve Snapinn, Mark E. Cooper, William E. Mitch, Barry M. Brenner Kidney International Volume 65, Issue 6, Pages 2309-2320 (June 2004) DOI: 10.1111/j.1523-1755.2004.00653.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Event rate of renal end points stratified by baseline albuminuria. The hazard ratio (HR) is shown at the top of each figure. The adjusted HR is corrected for all measured baseline risk markers summarized in the Statistical analysis section. Kidney International 2004 65, 2309-2320DOI: (10.1111/j.1523-1755.2004.00653.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Hazard ratio for renal events versus baseline albuminuria (left panels) and versus albuminuria at month 6 after treatment start (right panels). The hazard ratio (HR) with 95% CI is referenced at albuminuria <0.5g/g. Relation is corrected for all baseline risk markers summarized in the Statistical analysis section. Kidney International 2004 65, 2309-2320DOI: (10.1111/j.1523-1755.2004.00653.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Event rate of renal end points stratified by albuminuria change from baseline to 6months. The hazard ratio (HR) is shown at the top of each figure. The adjusted HR is corrected for all measured baseline risk markers, and month-6 changes summarized in the Statistical analysis section. Kidney International 2004 65, 2309-2320DOI: (10.1111/j.1523-1755.2004.00653.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Change in albuminuria (baseline compared to month 6) versus the hazard ratio of renal end point. The hazard ratio (HR) is adjusted for all baseline risk markers as well as the initial 6-month changes summarized in the Statistical analysis section. The HR with 95% CI is calculated relative to 0% change in albuminuria. Kidney International 2004 65, 2309-2320DOI: (10.1111/j.1523-1755.2004.00653.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 5 Hazard ratio for renal events versus albuminuria stratified for study drug. The left panel is the relation of the renal end point and end-stage renal disease (ESRD) against baseline albuminuria, The right panel is the relation between the renal end point and ESRD against month 6 albuminuria. Relation is corrected for baseline risk markers, as summarized in the Statistical analysis section. The <0.5g/g category in the placebo group was used as a common reference for the losartan and placebo groups. Kidney International 2004 65, 2309-2320DOI: (10.1111/j.1523-1755.2004.00653.x) Copyright © 2004 International Society of Nephrology Terms and Conditions